Key facts
- Mecwins’s last known valuation is $40.3M (Jul 2021).
- It has raised $9.4M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Almenara Capital Partners, Cross Road Biotech, EASME - EU Executive Agency for SMEs, Horizon 2020, Masela Inversiones — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Mecwins
- ·The full record, as it builds
Funding rounds
No funding rounds for Mecwins are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mecwins
Developer of a nanotechnological platform designed to produce sensitive immunoassays. The company's platform uses mechanical sensing technology based on a combination of nanomechanical sensing and plasmonic emission with a sandwich immunoassay, enabling researchers to get ultrasensitive detection systems for treating oncology, cardiovascular, and infectious diseases.
- Sector
- Healthcare
- HQ
- Madrid, Spain
- Founded
- 2008
- Employees
- 22
- Website
- mecwins.com/
- Ownership
- Privately Held (backing)
Mecwins doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mecwins shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mecwins in its N-PORT filings yet. We sweep new filings monthly.